Mucoadhesive gastroretentive microparticulate system for programmed delivery of famotidine and clarithromycin

Abstract

Aim

The present research was aimed to develop thiolated polyacrylic acid (TPA) based microspheres (MSPs) containing famotidine (FX) and clarithromycin (CLX).

Methods

TPA was synthesised from polyacrylic acid and l-cysteine in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC). The prepared TPA was characterised using FT-IR (Fourier transform-infra red), ¹H-NMR (proton nuclear magnetic resonance) spectroscopy, P-XRD (powder X ray diffraction) method, and zeta potential. The analytical tools have supported the formation of TPA. The thiolated microspheres were prepared by emulsion solvent evaporation method using 0.75% w/v polymer concentration and stirring at 400 rpm for 8 hr.

Results

The average particle size and zeta potential of optimised formulation was found to be 25.2 ± 1.87 μm and –26.68 mV, respectively. The entrapment efficiency of the optimised formulation was obtained 67.20% for FX and 70.20% for CLX. The developed microspheres were swelled only in 4 h from 0.5 to 0.9. The in vitro mucoadhesive study and in vitro drug release studies demonstrated that microspheres showed mucoadhesive property. In in vitro drug release studies, the release of FX and CLX were observed to be 58.68% and 60.48%, respectively from microspheres in 8 h. The thiolated microspheres showed higher adhesion time (7.0 ± 0.8 h) in comparison to the plain microspheres (2.6 ± 0.4 h).

Conclusion

The prepared TPA based mucoadhesive microspheres can be utilised as carriers for the treatment of peptic ulcer caused by Helicobacter pylori which will offer enhanced residence time for the rational drug combination in the gastric region.

Keywords:

• Microspheres
• mucoadhesive
• H. pyori
• ulcer
• famotidine
• clarithromycin

Acknowledgements

The authors are thankful to Sophisticated Instruments Centre and PURSE-PHASE II (DST) of Dr. H S Gour Vishwavidyalaya, Sagar MP India for providing instrumentation facility.

Disclosure statement

No potential conflict of interest was reported by the author(s).